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Abstract
Aims/hypothesis FTO gene single nucleotide polymor-
phisms (SNPs) have been shown to be associated with
obesity-related traits and type 2 diabetes. Several small
studies have suggested a greater than expected effect of
the FTO rs9939609 SNP on weight in polycystic ovary
syndrome (PCOS). We therefore aimed to examine the
impact of FTO genotype on BMI and weight in PCOS.
Methods A systematic search of medical databases
(PubMed, EMBASE and Cochrane CENTRAL) was con-
ducted up to the end of April 2011. Seven studies describing
eight distinct PCOS cohorts were retrieved; seven were
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genotyped for SNP rs9939609 and one for SNP rs1421085.
The per allele effect on BMI and body weight increase was
calculated and subjected to meta-analysis.
Results A total of 2,548 women with PCOS were included
in the study; 762 were TT homozygotes, 1,253 had an AT/
CT genotype, and 533 were AA/CC homozygotes. Each
additional copy of the effect allele (A/C) increased the
BMI by a mean of 0.19 z score units (95% CI 0.13, 0.24;
p02.26×10−11) and body weight by a mean of 0.20 z score
units (95% CI 0.14, 0.26; p01.02×10−10). This translated
into an approximately 3.3 kg/m2 increase in BMI and an
approximately 9.6 kg gain in body weight between TT and
AA/CC homozygotes. The association between FTO geno-
types and BMI was stronger in the cohorts with PCOS than
in the general female populations from large genome-wide
association studies. Deviation from an additive genetic mod-
el was observed in heavier populations.
Conclusions/interpretation The effect of FTO SNPs on
obesity-related traits in PCOS seems to be more than two
times greater than the effect found in large population-based
studies. This suggests an interaction between FTO and the
metabolic context or polygenic background of PCOS.
Keywords BMI . FTO . Meta-analysis . Polycystic ovary
syndrome . Systematic review .Weight
Abbreviations
AIC Akaike's information criterion
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LD Linkage disequilibrium
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Introduction
Obesity has reached epidemic proportions. In 2008, it was
estimated that 1.46 billion adults worldwide were overweight,
including 500 million obese individuals [1]. Both environ-
mental and genetic factors contribute to this phenomenon.
Several genes associated with obesity have recently been
identified by large scale genome-wide association studies,
one being the FTO gene located on chromosome 16q12.2
[2]. The FTO rs9939609 single nucleotide polymorphism
(SNP) and some other variants have been associated with
increased weight, raised BMI and several related traits [3–7].
This SNP has also been associated with higher odds of type 2
diabetes, although this effect can be entirely explained by its
impact on BMI in affected and unaffected individuals [3,
8–11]. This initial finding in European white cohorts has been
confirmed for other ethnicities [12], including Mexican [13]
and Asian [14–16] as well as African populations [17]. The
FTO rs9939609 SNP has two alleles, T and A, the latter being
a variant associated with risk of obesity [18]. It has been
demonstrated in multiple cohorts, mostly of white individuals,
that AA homozygotic individuals are on average 3 kg heavier,
with an increased BMI of about 0.8 kg/m2, than those without
the risk allele [3].
Polycystic ovary syndrome (PCOS) is a common endo-
crine disorder affecting 6–12% of women of reproductive
age, who present with hyperandrogenism, ovulatory dys-
function and polycystic ovaries [19–21]. Women with
PCOS are frequently obese, which significantly affects the
syndrome's clinical features by increasing the risk of insulin
resistance, type 2 diabetes and cardiovascular disease [22].
A study of the Polish population recently demonstrated a
substantially larger impact of the FTO rs9939609 polymor-
phism on weight in women with PCOS compared with the
previously reported weight difference in the general popu-
lation [23]. In this study, a 10 kg weight difference was
found between AA and TT homozygote PCOS carriers. In
addition, four other studies have reported a greater than
expected effect of the FTO gene on weight in cohorts with
PCOS [24–27]. However, all of these studies have been
characterised by a limited sample size and statistical power.
Furthermore, none of the CIs reported in the individual
PCOS population studies excluded the 3 kg difference found
in much larger studies of the general population.
Our study aims to perform a systematic review and meta-
analysis to fully define the effect of the FTO gene variants
on BMI and weight in PCOS women. Specifically, we
intended to determine whether the FTO rs9939609 SNP
and variants in linkage disequilibrium (LD) have a greater
impact on these traits in individuals with PCOS than in the
general population. A meta-analysis evaluating the relation-
ship between FTO and PCOS has never been conducted and
may provide new insight into this genetic association.
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Methods
Search strategy Relevant studies were identified by a sys-
tematic review of the literature via a search of the major
medical databases (PubMed, EMBASE and Cochrane CEN-
TRAL). The search strategy consisted of the following key
words: FTO, rs9939609, fat mass and obesity associated
protein, PCOS, polycystic, sclerocystic. Terms representing
outcome measures were omitted in order to increase the
sensitivity of the strategy and to elucidate all studies on a
given population regardless of their design and methodology.
This strategy was therefore considerably more sensitive than
the common strategies used in systematic reviews. Databases
were searched up to the end of April 2011 by two separate
reviewers. References of retrieved articles and abstracts of
presentations at international meetings (American Diabetes
Association, European Association for the Study of Diabetes)
were screened for the most up-to-date studies.
Inclusion and exclusion criteria All types of study investi-
gating women with PCOS were considered relevant, regard-
less of their design and hypothesis, provided that patients
were genotyped for the FTO rs9939609 SNP or for other
SNPs in strong LD. The authors of the identified publica-
tions were contacted in order to confirm the relevance of
each study and were invited to collaborate. Detailed data of
at least BMI or body weight had to be accessible for each
patient. Unpublished raw data on which to perform the
analyses were received from all of the authors except Tan
et al [27], who performed their own calculations (using the
same statistical methods) and submitted aggregated data
(mean values with SDs for each group representing different
genotypes). This procedure was associated with restriction
of the local Bioethical Committee from external access to
the raw data. Studies were excluded if patients were not
genotyped for the rs9939609 polymorphism or any other
SNP in LD, and if the authors declined or did not respond to
the invitation to collaborate.
Outcome measures Per allele change in effect on BMI
and body weight were assessed.
Statistical analysis Distributions of BMI were skewed in
most cohorts; therefore, log10 transformation was performed
in order to obtain a normal distribution. It was expected that
the distribution of BMI in women with PCOS would differ
from that of the general population; hence, data were stand-
ardised to the z score units of SD. z scores were obtained by
dividing the difference between each logBMI value and the
mean logBMI of the entire cohort by the SD of the logBMI
values. The same transformation and standardisation was
applied to body weight. Robust linear regression in the addi-
tive model was performed in order to test the association
between genotypes and anthropometric measures. Individual
study results were then pooled in a meta-analysis with a fixed
inverse variance effect model. The overall effect was tested
with the Z test assuming p<0.05 as the level of significance.
All effect sizes were presented as means with a 95% CI.
Heterogeneity between studies was assessed by applying
Cochran χ2 test and was considered significant at p<0.1.
Meta-analyses were carried out using Sophie ver. 1.5 Software
developed by HTA Consulting (Krakow, Poland). Publication
bias was assessed for the difference in BMI between the AA
and TT genotypes with the use of both the Egger and Begg
tests, with p<0.05 considered statistically significant. Hardy–
Weinberg equilibrium (HWE) was tested using the DeFinetti
program (available from http://ihg.gsf.de/cgi-bin/hw/hwa1.pl,
accessed 24 February 2012).
In addition, in order to allow a comparison with one of
the external control cohorts, an association between the BMI
and the FTO variants was also calculated after rank-based
inverse normal transformation of the BMI values. Data
regarding BMI were also adjusted for patients' ages by
including the variable as a covariate in a linear regression
model in order to exclude a potential confounding effect of
this trait. To provide an approximate estimate of the per
allele effect size in BMI units (kg/m2), the aggregated effect
sizes in z score units were translated into BMI units using
SD values from the entire PCOS population, yielding
8.619 kg/m2. The same procedure was applied to body
weight, in which z score units were multiplied by the SD
from the entire PCOS population, yielding 24.065 kg.
The effect of the FTO mutations on BMI in the subset of
women with PCOS was statistically compared with the
results obtained from genome-wide association studies.
First, the data were compared with unpublished data pro-
vided by the GIANT Consortium, which investigated an
association between rs1558902 FTO polymorphisms and
BMI increase expressed in SD units. The available data
from 80 studies included 109,955 adult women of European
ancestry with characteristics that had previously been de-
scribed [6]. These data were considered relevant as
rs1558902 is localised to intron 1 and is in complete LD
with rs9939609 (r200.934 and D'00.966 according to
HapMap release 22). Another reference source came from
the published data from Frayling et al, who investigated 11
cohorts, including over 18,800 adult women [3]. Their find-
ings reported an increase in BMI associated with the
rs9939609 polymorphism, expressed as a per A-allele in-
crease in z score units. Both reference results were unad-
justed for age. Results from the entire female subpopulation
were compared with those from the population with PCOS.
Due to limited precision of the data published by Frayling et
al, a conservative worst case scenario approach was adopted
by using the highest possible mean value and SE that still
fitted the common rule for rounding numerical values. Both
2638 Diabetologia (2012) 55:2636–2645
the Z test and the χ2 test for heterogeneity were used to
compare effect size in the population with PCOS for each
reference group. However, owing to the consistent results of
both statistical approaches, only one common p value was
presented for each comparison [28].
To determine the genetic model exhibiting the best fit, a
correlation between genotype and phenotype expressed in
per allele increase in logBMI z score units was assessed
using linear regression [29]. Ordinal variables were assigned
to each genotype according to the number of A/C alleles
(i.e. TT00, AT/AC01, AA/CC02). Additive, recessive and
dominant models were tested, and the model with the lowest
Akaike's information criterion (AIC) was considered best
fitting. Meta-regression using the restricted maximum like-
lihood model was performed in order to explain deviation
from the additive model.
Results
Twenty-nine records were identified in the systematic search
of the medical databases, of which 14 were considered
potentially relevant and underwent further assessment after
exclusion of duplicates and abstract analysis. Six papers
were subsequently excluded due to reasons presented in
the PRISMA diagram (Fig. 1). The eight remaining studies
were initially included, and their authors were contacted in
order to confirm eligibility. The authors of seven studies,
which included data regarding eight distinct cohorts, met the
inclusion criteria and agreed to collaborate in this study. One
study of the Chinese population presented data relevant to
our hypothesis; however, since the authors did not respond
to an invitation to participate and to provide data, this study
was excluded [30].
Study characteristics The studies included were conducted
in six European countries (Austria, Czech Republic,
Germany, Poland, Romania, UK) and in the USA [23–27,
31, 32]. All of the study participants from the European
centres were white, whereas in the American cohort partic-
ipants were grouped as white 91%, Hispanic 3% and Afri-
can–American 1%, with 5% categorised as unknown or
other. The characteristics of the populations investigated
are shown in Table 1. Overall, white participants represented
97% of the entire group. In six studies, patients were geno-
typed for the FTO rs9939609 SNP and in only one study for
rs1421085 [32], which is in complete LD with rs9939609
(r200.934 and D'00.966 according to HapMap release 22).
The study size ranged from 136 to 469, with a total of 2,548
women with PCOS included in the analysis for whom at
least BMI or body weight was available. Of these, 762 were
TT homozygotic patients, 1,253 had an AT/CT genotype,
and 533 were AA/CC homozygotic for rs9939609 and
rs1421085. The distribution of the genotype was generally
consistent across the cohorts, and the observed A/C allele
frequency ranged from 42% to 52%. Genotype distribution
of all cohorts was consistent with HWE.
The mean age of the population with PCOS ranged from
25 to 32 years old. Mean BMI ranged from 26.44 to
35.37 kg/m2, with patients weighing least in Austria and
the heaviest study cohort originating from the USA. Mean
weight ranged from 73.01 to 95.76 kg. Data regarding body
weight were not available for one study [32].
Anthropometric traits Data regarding BMI were available
for a total of 2,510 women with PCOS. Of these, 746 were
TT homozygotes, 1,239 women were AT/CT heterozygotes,
and 525 patients had an AA/CC genotype. A strong associ-
ation between the FTO variants and BMI was revealed.
Each additional copy of the effect allele increased BMI by
a mean of 0.19 z score units (95% CI 0.13, 0.24; p02.26×
10−11), equivalent to approximately 1.62 kg/m2 (Fig. 2). No
heterogeneity between the studies was noted (p00.9217,
I200%). This association remained almost unaffected even
after data were adjusted for age (0.18 z score units, 95% CI
0.12, 0.23; p01.30×10−10, equivalent to 1.55 kg/m2).
Data regarding body weight were available for a total of
2,161 individuals with PCOS, including 648 women in the
TT group, 1,068 women with an AT genotype, and 445
Full-text articles assessed for 
eligibility 
(n=14)
Studies included in  
qualitative synthesis 
(n=8)
Studies included in 
quantitative synthesis –  
based on full data 
(n=7)
Full-text articles excluded with 
reasons 
(n=6) 
Reasons for exclusion: 
Review – 1 
Additional abstracts consistent 
with included studies – 5 
Records screened 
(n=23) 
Records excluded 
(n=9) 
Records after duplicates removed 
(n=23) 
Records identified through 
database searching 
(n=29)
Additional records identified 
from reference list 
(n=0)
Fig. 1 PRISMA diagram of the study selection process
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patients with an AA genotype. Meta-analysis of the seven
cohorts revealed that, in the women with PCOS, each addi-
tional copy of the effect allele was associated with a body
weight increase of a mean of 0.20 z score units (95% CI
0.14, 0.26; p01.02×10−10), which is equivalent to approx-
imately 4.79 kg (Fig. 3). This effect was highly consistent
across the studies and no evidence of heterogeneity was
observed (p00.9388, I200%).
Comparison between PCOS cohorts and the general female
population The observed FTO-associated increase in
BMI in women with PCOS was larger than the
corresponding effect found in the 109,955 women from
the GIANT Consortium cohort (p00.0002) (Fig. 4a) [6].
The association between examined polymorphisms and
BMI in women with PCOS was also stronger than
previously reported by Frayling et al [3] for the general
female population (p00.0146) (Fig. 4b). When PCOS
data were corrected for age, the impact of FTO on
BMI remained significantly greater when comparing
the effect sizes of both the GIANT Consortium cohort
(p00.0005) and the female cohort described by Frayling
et al [3] (p00.0298).
Genetic model analysis Analysis of inheritance revealed
that the study populations fitted different genetic models.
The data from four trials [23, 25, 26, 31] fit very well with
an additive model, whereas the recessive model was the best
fit for the remaining populations [24, 27, 32] (Table 2). The
degree of the deviation from an additive model was clearly
associated with the mean BMI value in the TT subgroup,
which was shown by meta-regression (p00.0033) (Fig. 5a).
Fig. 2 Inverse variance (IV) meta-analysis of per allele (A/C) effect
increase in log-transformed BMI, expressed in z score units. Forest plot
and corresponding values represent point estimates for per allele effect
together with 95% CI. Pooled weighted mean difference effect size
with 95% CI is also shown. Each cohort is represented by the name of
the first author. Test for heterogeneity: Q02.57, df07, p00.9217, I20
0.00%. Test overall effect: z06.69, p<0.0001
Fig. 3 Inverse variance (IV) meta-analysis of per allele (A) effect
increase in log-transformed body weight, expressed in z score units.
Forest plot and corresponding values represent point estimates for per
allele effect together with 95% CI. Pooled weighted effect size with
95% CI is also shown. Each cohort is represented by the name of the
first author. Test for heterogeneity: Q01.78, df06, p00.9388, I20
0.00%. Test overall effect: z06.46, p<0.0001
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A single copy of the effect allele was associated with a
significant increase in logBMI z score in only one trial,
with the lowest mean BMI in the homozygous TT
group [25]. A phenotypic manifestation of the hetero-
zygotic FTO variant was also observed in three
subsequent studies, with the lowest mean BMI in the
TT group; however, the difference did not reach statis-
tical significance, probably because of low power [23,
26, 31]. In the four remaining trials with a higher mean
BMI in the TT group (≥28 kg/m2), a single copy of the
effect allele did not cause any apparent gain in BMI
(Fig. 5a). The association between the phenotypic man-
ifestation of the heterozygous FTO polymorphism and
the extent of obesity in each cohort was also replicated
with respect to change in body weight z score units (p0
0.0041) (Fig. 5b). Conversely, phenotypic manifestation
of homozygous AA/CC variants was independent of mean
BMI or mean body weight in the TT group (data not
shown).
Publication bias No apparent publication bias was found by
either visual inspection of the funnel plot or formal statisti-
cal tests: Egger's regression test (p00.217) or Begg's rank
correlation test (Kendall's tau00.357, p00.275).
Discussion
Recent investigations have shed light on the genetic mech-
anism of adiposity and related traits. Several large studies
have demonstrated an association between FTO gene poly-
morphisms and weight, BMI and related traits [3, 6, 7].
Moreover, the FTO rs9939609 SNP was also associated
with PCOS, and its effect was mediated, as in the general
population, by adiposity [26]. Interestingly, it was postulat-
ed in the within-patient analysis that the impact of this
particular genetic variant could be larger in individuals
with PCOS than in the general population [23]. A greater
effect of rs9939609 SNP variants on weight-related var-
iables in women with PCOS was also observed in several
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Fig. 4 Comparison of the effect of the FTO polymorphism on BMI
between women with PCOS and the general female population from
the GIANT Consortium (a) and the study of Frayling et al [3] (b).
White columns represent the per allele effect increase in the PCOS
population, whereas grey columns represent the corresponding effect
calculated for the general population. Data are expressed as either rank-
based inverse normally transformed BMI (a) or log-transformed BMI z
scores (b). Error bars represent SE. Comparison between cohorts was
performed with a two-sided t test. †p00.0002 for comparison between
women with PCOS and the general female population from the GIANT
Consortium. *p00.0146 for comparison between women with PCOS
and the general female population described by Frayling et al [3]
Table 2 Linear regression analysis for assessing association be-
tween genotype and per allele logBMI z score according to
additive, recessive and dominant models. Slopes together with
p value and AIC are given for each regression test. The best-
fitting genetic model was selected on the basis of the lowest
value of AIC
Population Mean BMI of TT
variants (kg/m2)
Additive Recessive Dominant Best-fitting model
β p value AIC β p value AIC β p value AIC
Vcelak et al [31] 25.2 0.28 0.002 −7.1 0.33 0.040 −1.2 0.41 0.002 −6.3 Additive
Wehr et al [25] 25.2 0.17 0.055 −0.7 0.18 0.254 1.7 0.25 0.058 −0.6 Additive
Kowalska et al [23] 26.1 0.28 0.015 −2.9 0.32 0.094 0.2 0.46 0.018 −2.6 Additive
Barber et al [26] 27.6 0.15 0.022 −2.2 0.22 0.062 −0.5 0.20 0.062 −0.5 Additive
Attaoua et al [32] 28.0 0.22 0.026 −2.0 0.42 0.010 −3.7 0.18 0.265 1.8 Recessive
Tan et al [27] 30.9 0.18 0.014 −3.0 0.44 0.0004 −7.5 0.07 0.539 4.7 Recessive
Ewans (PCOS cases) et al [24] 32.1 0.18 0.016 −2.8 0.37 0.005 −4.7 0.14 0.190 1.3 Recessive
Ewans (PCOS families) et al [24] 34.99 0.15 0.025 −2.0 0.39 0.001 −8.6 0.05 0.662 2.8 Recessive
2642 Diabetologia (2012) 55:2636–2645
other studies [24–27]. However, none of these studies
was adequately powered to confirm that the greater effect
in women with PCOS was significantly different from
that in the general population.
In this study, a meta-analysis demonstrated that each addi-
tional copy of the effect allele (A/C) was associated with an
average increase in BMI of 0.19 z score units and a mean
weight gain of 0.20 z score units. This corresponded to around
a 3.3 kg/m2 and a 9.6 kg difference in BMI and body weight
units, respectively, between TT and AA/CC homozygotes.
Importantly, this effect was highly consistent between the
PCOS studies included in this meta-analysis, with no evidence
of heterogeneity between the analysed populations. The
impact of FTO variants on BMI and weight is significantly
stronger than those observed for the general female population
as reported in the previous studies of FTO conducted on adult
participants not selected for PCOS [3, 6, 15, 33–35].
Unexpectedly, the analysis revealed a variation between
the studies with regard to the inheritance model of the FTO
polymorphisms, which seemed to be related to the BMI in
the investigated populations. Phenotypic manifestation of
the heterozygous FTO variant existed only in studies with
the lowest mean BMI in the TT group. In trials with a higher
mean BMI in the TT group, a single variant of an effect
allele was not associated with an apparent increase in obe-
sity indices. For those studies, the recessive model fits best.
To our knowledge, this phenomenon has not been observed
in the general population.
The current study has several possible limitations. First,
our PCOS cohorts with a mean age ranging from 25 to
32 years old were younger than those reported in the general
female population studies. Effect sizes adjusted for age were
not available for either reference group, either as unpub-
lished data or from earlier publications [3, 6]. Neverthe-
less, the age adjustment in women with PCOS had a
very limited impact on both the observed association
between FTO and BMI and the results of comparisons
between the patients with PCOS and the women in the
general population, which remained almost unchanged.
Moreover, the FTO-associated increase in BMI reported
by Frayling et al [3] was comparable in the young and
older cohorts, with no evidence of between-group hetero-
geneity. The per allele increase in logBMI z scores in the
young female ALSPAC Mothers cohort (N06,376; mean
age 28.4 years) and the NFBC1996 cohort (N02,306;
each patient sampled at 31 years old) was not signifi-
cantly different from the effect size observed in elderly
women from the BWHS cohort (N03,244; mean age
68.8 years) as shown by the heterogeneity test (p00.79;
I200%, for all three cohorts) [3]. It thus seems unlikely
that the effect of FTO variants on BMI in PCOS is due
to the young age of the women examined.
Another possible limitation includes a lack of direct
comparison with control cohorts consisting of women with-
out PCOS matched with the analysed study populations.
Such comparisons were either not made in the original
studies [23, 25, 27] or were based on a very limited sample
size, precluding quantitative analysis [24]. Nevertheless, we
compared our study data with results, published and unpub-
lished, from two large cohorts representing the general
female population (GIANT Consortium, unpublished data)
[3]. This analysis showed a statistically larger effect of the
FTO variants in PCOS than in the reference groups [3, 6].
Second, although the possibility of a publication bias in
reports examining the impact of the FTO gene in PCOS
cannot be entirely excluded, it seems unlikely in light of the
Fig. 5 Mixed-effect meta-regression analysis correlating the mean
difference in (a) log-transformed BMI z score units between AT/CT
and TT (dependent variable) and mean BMI in the TT group as
independent variable or (b) log-transformed body weight z score units
between AT and TT (dependent variable) and mean body weight in the
TT group (independent variable). The solid lines indicate the predicted
effects with 95% CI (dashed lines). Circles represent point estimates
for each cohort. Study weight is represented by the diameter of the
corresponding circle. Error bars represent the SE of each point esti-
mate. Dotted lines represent a lack of phenotypic difference between
the TT and AT/CT polymorphism. There was a statistically significant
inverse correlation between mean BMI in the TT group and the AT-
associated increase in logBMI (β0−0.0381, p00.0033). Similarly, a
significant inverse correlation was observed between mean body
weight in the TT group and the AT-associated increase in log-body
weight (β0−0.0161, p00.0041)
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results of the statistical tests (Egger's and Begg's tests).
Moreover, all studies regarding PCOS and the FTO gene
were included even if they were originally designed not to
test for the difference in impact of the FTO genotypes on
weight or BMI.
The sample size of 2,548 individuals is smaller than
those of many genetic studies comparing effect sizes. In
part, this number reflects the limited number of studies in
which PCOS women were genotyped for the FTO SNP
as we included all available studies referring to FTO in
PCOS. The problem of the limited number of PCOS
patients who were genotyped may be, at least in part,
associated with the need to follow a diagnostic algorithm
for this disease that is costly and time-consuming. We
acknowledge that, while our study tested the hypothesis
that FTO genetic variation has a greater impact on BMI
and body weight in the context of PCOS, a biological
explanation for this phenomenon remains to be elucidat-
ed. The unique metabolic setting of PCOS, which
includes significant alterations in sex steroid hormone
levels (hyperandrogenaemia and significant extraglandular
aromatisation of androgens), reduced sex hormone-
binding globulin levels, and insulin resistance, may mod-
ify the influence of the FTO genotypes [36]. Alternative-
ly, gene–gene interactions may contribute to the greater
influence of FTO. Further studies are needed to elucidate
the roles of biochemical and genetic factors affecting the
action of FTO in PCOS.
The major studies that have demonstrated an impact of
FTO on body weight have been conducted primarily on
white populations [3, 37–39]. This initial finding in white
cohorts was confirmed in a Mexican population as well as in
multiple studies including a recent large-scale meta-analysis
of the East and South Asian population [12, 14–16]. In spite
of initial data suggesting that FTO had no clear impact on
phenotype in African cohorts [40], the effect of the gene
variants on obesity was eventually established in a new
genome-wide association study in a population with a pre-
dominantly African ancestry in the USA [17]. The lack of
effect in the initial African study may have been due to the
impact of environmental circumstances, such as seasonal
food shortages and high physical activity in the African
population [40, 41].
Results from one study of the Chinese population,
which could not be included in our meta-analysis due
to a lack of numerical data, suggested no clear associa-
tion between FTO allelic variation and obesity-related
traits in both healthy individuals and women with PCOS
[30]. Subjects from studies included in our meta-analysis
were mainly white. Consequently, our findings cannot be
generalised to other ethnic groups. Our observations
might not be specific to PCOS, as there might exist
other phenotypes and diseases in which the effect of
the FTO genotypes is larger than in the general popula-
tion. Finally, we should point out that a slightly greater
effect of FTO genotypes was observed in heavier diabetic
cohorts than in the general population [3]. Nevertheless,
the magnitude of the current finding and its presence in
obese and non-obese populations with PCOS suggest that
it has a different mechanism in PCOS.
In conclusion, our meta-analysis, based on eight distinct
cohorts, shows that the per allele effect of FTO polymor-
phisms on BMI and weight seems to be more than two times
greater than the effect found in large population-based stud-
ies. Our results suggest that the metabolic context or specific
polygenic background of PCOS modifies the influence of
FTO on weight and BMI.
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